Since the immunogenic lipopeptide conjugates may be attacked by enzymes after administration, we systematically develop enzyme resistant analogues. Unspecific esterases may slowly degrade the lipid part of the nitrogen and proteases can hydrolyse the peptide moiety. This degradation of the lipopeptide adjuvants counteracts to a longer lasting immuno adjuvant activity. Lipopeptides, which are stable against proteases and esterases, should therefore be more potent adjuvants.
Since the immunogenic lipopeptide conjugates may be attacked by enzymes after administration, we systematically develop enzyme resistant analogues. Unspecific esterases may slowly degrade the lipid part of the nitrogen and proteases can hydrolyse the peptide moiety. This degradation of the lipopeptide adjuvants counteracts to a longer lasting immuno adjuvant activity. Lipopeptides, which are stable against proteases and esterases, should therefore be more potent adjuvants.
Since it was not advisable to change too many structural parameters simultaneously and because of the tedious multistep synthesis of the lipopentapep tide, we decided to improve the protease resistance at first. Therefore the lipopeptide 12 ( Fig. 1) was synthesized, which has the amino acid sequence of TPP with the only difference that both serine re sidues are substituted by two a-methylserine re sidues.
Peptide syntheses using a-methylserine were reported recently [5] . Similar to a-methylalanine (Aib) peptides [6 , 7] a-MeSer-peptides should adopt conformationally strongly restricted structures. a-Methylserine containing peptides are not degradable by proteases [8 ] , therefore carboxypeptidases can degrade this lipopeptide only to the lipotripeptide or lipotetrapeptide. Since Pam3Cys-Ser was found to exhibit about 50% of the biological activity of the complete lipoprotein [9] one would expect mitogenic activity also for Pam3Cys-a-MeSera-MeSer. However, the mitogenic activity of 12 could be considerably altered due to configurational or conformational effects of the sterically hindered [R]-a-MeSer residues respectively. 
Experimental Part

Benzylcarbonyl-[ R]-O-tert-butyl-a-methylserine ( Z-
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Results and Discussion
The synthesis of the lipopentapeptide 12 ( Fig. 1) includes a 2+ 2 MeSer(OBu')-a-M eSer(OBu')-OH (7) (Fig. 2 ) shows no signals splitting, which proves that the sample contains only one diastereomer.
The key step of the successful synthesis is also proved by the FD-MS of the fully protected lipopen tapeptide 11 (Fig. 3) served. This is an encouraging result for the design of more lipopeptide analogs of this type.
In long-term in vivo experiments the immunoadjuvant activity of lipopeptide 1 
